Results from evoke and evoke+: Two phase 3, randomised, placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer’s disease
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.